Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 4/20 | 0.36 |
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.36 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455193 | 0.98 | — | — | |
| SCHEMBL866509 | 0.98 | — | — | |
| SCHEMBL232854 | 0.98 | — | — | |
| SCHEMBL9480609 | 0.83 | SOAT1 (0.38) | PPARGPPARDPPARAFAAH | |
| SCHEMBL9480599 | 0.83 | SOAT1 (0.38) | PPARGPPARDPPARAFAAH | |
| SCHEMBL29957177 | 0.82 | S1PR1 (0.38) | LMNAFAAHEPHX2ALKBH5SUCNR1 | |
| SCHEMBL866402 | 0.80 | GRIK1 (0.50) | CYP1A2 | |
| SCHEMBL865038 | 0.80 | GRIK1 (0.50) | CYP1A2 | |
| SCHEMBL11694674 | 0.77 | — | — | |
| SCHEMBL526332 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-1984384-B1 | Conotoxin analogues, and methods for synthesis of intramolecular dicarba bridge containing peptides | SYNGENE LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-8759480-B2 | Contoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2014-06-24 | — | — | US | disclosed |
| EP-1984386-B1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LTD (AU) | 2013-10-09 | — | — | EP | disclosed |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-05-16 | — | — | US | disclosed |
| US-8362204-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2013-01-29 | — | — | US | disclosed |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2012-06-07 | — | — | US | disclosed |
| US-8188217-B2 | — | — | 2012-05-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | MONASH UNIVERSITY (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | SYNGENE LIMITED (AU) | 2009-06-04 | — | — | US | disclosed |
| US-7538190-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2009-05-26 | — | — | US | disclosed |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | OTC, NBAS, IDH2 | PPARG 4013/4885TOP1 721/4885CHRM1 4393/4885 |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, CDCA2 | PPARG 4548/4885TOP1 791/4885CHRM1 2831/4885 |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | OTC, NBAS, IDH2 | PPARG 4013/4885TOP1 721/4885CHRM1 4393/4885 |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | VIP, CANX, INHA | PPARG 4868/4885TOP1 4381/4885CHRM1 2511/4885 |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | VIP, CANX, PDIA5 | PPARG 4855/4885TOP1 4293/4885CHRM1 2248/4885 |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | PPARG 4498/4885TOP1 869/4885CHRM1 2760/4885 |
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, MTCL3 | PPARG 4498/4885TOP1 869/4885CHRM1 2760/4885 |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | OTC, NBAS, IDH2 | PPARG 4013/4885TOP1 721/4885CHRM1 4393/4885 |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | VIP, NRDC, INHA | PPARG 4883/4885TOP1 4547/4885CHRM1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.